Examkin

Soru

Zorluk: ZorImmunizations and Vaccine-Preventable Diseases

A 15-month-old girl is evaluated in the pediatric immunology clinic. She was diagnosed with 22q11.2 deletion syndrome shortly after birth when she presented with hypocalcemic tetany. She has a history of recurrent viral respiratory infections and oral candidiasis. Current medications include calcium supplementation and trimethoprim-sulfamethoxazole. Her physical examination is notable for micrognathia, low-set ears, and a harsh systolic ejection murmur at the left upper sternal border. Recent laboratory evaluation reveals an absolute CD3+ T-lymphocyte count of 350 cells/mm3350 \text{ cells/mm}^3 (normal for age: 1,5001,500–5,000 cells/mm35,000 \text{ cells/mm}^3). The parents inquire about her 12-to-15-month immunizations, noting she has received all her recommended inactivated infant vaccines but has not yet received the measles-mumps-rubella (MMR) or varicella vaccines. Which of the following is the most appropriate next step regarding her immunizations?

  1. A
    Proceed with the administration of both the measles-mumps-rubella and varicella vaccines today
  2. B
    Give both the measles-mumps-rubella and varicella vaccines at half their standard doses
  3. C
    Administer the measles-mumps-rubella vaccine but defer the varicella vaccination
  4. D
    Provide the varicella vaccine but strictly avoid the measles-mumps-rubella vaccine
  5. Strictly withhold both the measles-mumps-rubella and varicella vaccines at this timeCevap

Cevap

Strictly withhold both the measles-mumps-rubella and varicella vaccines at this time.
The correct action is to strictly withhold both the measles-mumps-rubella (MMR) and varicella vaccines. This patient has 22q11.2 deletion syndrome (DiGeorge syndrome), which is characterized by the classic triad of conotruncal cardiac anomalies (e.g., tetralogy of Fallot, indicated by her murmur), hypoplastic thymus (leading to cellular immunodeficiency), and hypocalcemia (secondary to parathyroid hypoplasia). Her history of recurrent fungal infections (candidiasis) and need for *Pneumocystis jirovecii* prophylaxis reflect significant underlying T-cell impairment.

The MMR and varicella vaccines are live-attenuated vaccines. In immunocompetent hosts, these vaccines cause a subclinical or mild infection that induces robust, long-lasting immunity. However, in patients with profound cellular immunodeficiency, the attenuated virus can replicate unchecked, leading to severe, disseminated, and potentially fatal vaccine-strain disease.

For patients with DiGeorge syndrome, the decision to administer live vaccines depends on the degree of T-cell impairment. Current advisory committee guidelines state that for children aged 1 to 5 years, live-attenuated vaccines are absolutely contraindicated if the absolute CD3+ T-lymphocyte count is **<500 cells/mm3< 500 \text{ cells/mm}^3**. Because this patient's CD3+ count is 350 cells/mm3350 \text{ cells/mm}^3, both the MMR and varicella vaccines must be strictly withheld. Inactivated vaccines (such as DTaP, Hib, and IPV) remain safe and are highly recommended for immunocompromised patients, although their immunogenicity may be reduced.

Adım Adım Çözüm

1
Identify the patient's underlying condition and immune status.
The patient has DiGeorge syndrome (22q11.2 deletion) complicated by severe cellular immunodeficiency, evidenced by a CD3+ T-lymphocyte count of 350 cells/mm3350 \text{ cells/mm}^3.
DiGeorge syndrome causes thymic hypoplasia and variable T-cell deficiency, which dictates vaccine safety.
2
Determine the safety threshold for live vaccines in this condition.
Current guidelines strictly contraindicate live-attenuated vaccines if the absolute CD3+ T-lymphocyte count is <500 cells/mm3< 500 \text{ cells/mm}^3 in children aged 1 to 5 years.
Adequate T-cell function is required to mount an immune response and prevent the attenuated vaccine strain from causing disseminated disease.
3
Categorize the requested vaccines.
Both the measles-mumps-rubella (MMR) and varicella vaccines are live-attenuated viral vaccines.
Vaccine classification determines whether they can be safely administered to immunocompromised hosts.
4
Formulate the management plan.
Because the patient's CD3+ count (350 cells/mm3350 \text{ cells/mm}^3) falls below the safety threshold, both live vaccines must be strictly withheld.
Administering them risks severe, potentially fatal vaccine-strain infection.

Anahtar Kavram

Live-attenuated vaccines are contraindicated in patients with severe cellular immunodeficiency due to the risk of disseminated vaccine-strain disease. In 22q11.2 deletion syndrome, live vaccine administration requires an absolute CD3+ count of ≥500 cells/mm3\geq 500 \text{ cells/mm}^3 (for ages 1-5 years).

Vaccine TypeExamplesSafety in Severe T-cell Deficiency
Live-AttenuatedMMR, Varicella, Rotavirus, Intranasal Influenza, Yellow FeverContraindicated
Inactivated / ToxoidDTaP, IPV, IM Influenza, Hepatitis B, Hib, PCVSafe / Recommended
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Immunizations and Vaccine-Preventable Diseases

Bu konudan daha fazla soru